Literature DB >> 10178662

The role of government and private insurers in guiding and implementing pharmacoeconomic analyses.

D A Freund1, B R Luce.   

Abstract

Mesh：

Year:  1998        PMID： 10178662     DOI： 10.2165/00019053-199813040-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

Authors:  I S Udvarhelyi; G A Colditz; A Rai; A M Epstein
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

2.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential.

Authors:  M Drummond; A Brandt; B Luce; J Rovira
Journal:  Int J Technol Assess Health Care       Date:  1993       Impact factor: 2.188

4.  Cost-effectiveness analyses.

Authors:  E P Steinberg
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.